The Finlay Vaccine Institute published, on its Twitter account, the final results of the phase three clinical trial of Soberana-02, a study that was randomized, double-blind and placebo-controlled.

The prestigious scientific institution highlighted that this safe and effective vaccine against Covid-19, with only two doses, obtained an efficacy of 71 percent against circulating beta and delta strains.

The third dose of Soberana Plus increased the effectiveness up to 92.4 percent, highlighted the Finlay Vaccine Institute on its official Twitter account.

The results indicate that Soberana-02 is a promising vaccine that can be used in a two-dose regimen or in a heterologous three-dose combination with Soberana Plus.